Your browser doesn't support javascript.
loading
Should Calcineurin Inhibitors/Sirolimus Be Ceased Completely In Posterior Reversible Encephalopathy Syndrome?
Karatas, Cihan; Akyollu, Basak; Arpali, Emre; Kocak, Burak.
Afiliação
  • Karatas C; Department of Organ Transplantation, Koc University Hospital, Istanbul, Turkey. Electronic address: ckaratas@kuh.ku.edu.tr.
  • Akyollu B; Department of Organ Transplantation, Koc University Hospital, Istanbul, Turkey.
  • Arpali E; Department of Organ Transplantation, Koc University Hospital, Istanbul, Turkey.
  • Kocak B; Department of Organ Transplantation, Koc University Hospital, Istanbul, Turkey.
Transplant Proc ; 56(1): 93-96, 2024.
Article em En | MEDLINE | ID: mdl-38171990
ABSTRACT

BACKGROUND:

To investigate the relationship between immunosuppressive treatments and posterior reversible encephalopathy syndrome (PRES) in transplant patients.

METHODS:

We presented a retrospective study of 4 cases of PRES in transplant patients. Patient records were reviewed to identify potential risk factors, clinical presentations, radiological findings, and immunosuppressive treatments used.

RESULTS:

Our analysis revealed a potential association between immunosuppressive treatments and the development of PRES in transplant patients. Specifically, we found that adjusting or switching immunosuppressive treatments can improve outcomes and prevent the recurrence of PRES.

CONCLUSION:

Our findings highlight the importance of recognizing PRES as a potential complication of immunosuppressive treatments in transplant patients. Early detection and management, including a review of immunosuppressive treatments, may improve patient outcomes and prevent further complications.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome da Leucoencefalopatia Posterior / Inibidores de Calcineurina Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome da Leucoencefalopatia Posterior / Inibidores de Calcineurina Idioma: En Ano de publicação: 2024 Tipo de documento: Article